4.6 Article

Outcomes With Post-Dilation Following Transcatheter Aortic Valve Replacement

期刊

JACC-CARDIOVASCULAR INTERVENTIONS
卷 7, 期 7, 页码 781-789

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcin.2014.02.013

关键词

aortic stenosis; paravalvular regurgitation; post-dilation; prosthesis-patient mismatch; reballooning; transcatheter aortic valve replacement

资金

  1. Philips Healthcare
  2. Edwards Lifesciences
  3. Boston Scientific Corporation
  4. AstraZeneca
  5. Bristol Myers Squibb
  6. Daiichi-Sankyo/Eli Lilly
  7. GlaxoSmithKline
  8. Janssen
  9. Merck/Schering-Plough
  10. Regeneron
  11. St. Jude Medical
  12. Abbott Vascular
  13. Medtronic
  14. Siemens
  15. Paieon
  16. Cordis
  17. MicroInterventional Devices
  18. Lantheus Medical Imaging
  19. GE Healthcare
  20. Boston Scientific

向作者/读者索取更多资源

Objectives This study sought to characterize the patients receiving post-implantation balloon dilation (PD) following transcatheter aortic valve replacement (TAVR) and evaluate procedural outcomes in the PARTNER (Placement of Aortic Transcatheter Valve) I trial. Background Following TAVR, PD has been used to treat paravalvular regurgitation. Methods The PARTNER I trial cohort A (n = 304) and cohort B (n = 194) patients randomized to TAVR and the nonrandomized continued access TAVR (n = 1,637) patients were included in the analysis. PD was performed at the discretion of the operator. Clinical events and echocardiographic variables were collected prospectively out to 1 year. Results The overall incidence of PD was 12.4%. PD patients had significantly less prosthesis-patient mismatch (p < 0.001) and larger effective orifice areas (p < 0.001) throughout the follow-up period. There were significantly more subacute strokes (occurring <7 days: 4.9% vs. 2.6%; p = 0.04) in PD patients but no difference in late stroke, either at 7 to 30 days (0.0% vs. 0.8%; p = 0.16) or >30 days (1.9 vs. 1.7%; p = 0.75). Although there was no significant increase in early mortality with PD, at 1 year, there was a trend for higher all-cause mortality (p = 0.054) and a significant difference in death or stroke (p = 0.04). When the subgroup of patients with none/trace paravalvular regurgitation were evaluated, there was no significant association of PD with mortality (p = 0.61) and death or stroke (p = 0.96). Multivariable analysis failed to show a relationship between PD and mortality. Conclusions PD is associated with reduced rates of moderate or severe prosthesis-patient mismatch with no evidence for short-term structural deterioration of the balloon-expandable transcatheter valve. Although PD is associated with a greater incidence of early stroke, there is no significant association between PD and stroke beyond 7 days. Multivariable analysis shows no significant association between PD and mortality. (J Am Coll Cardiol Intv 2014; 7: 781-9) (C) 2014 by the American College of Cardiology Foundation

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据